Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials,The Lancet Diabetes & Endocrinology

当前位置： X-MOL 学术 › Lancet Diabetes Endocrinol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials
The Lancet Diabetes & Endocrinology ( IF 44.0 ) Pub Date : 2024-07-08 , DOI: 10.1016/s2213-8587(24)00155-4
Ellen M Apperloo ₁ , Brendon L Neuen ₂ , Robert A Fletcher ₃ , Niels Jongs ₁ , Stefan D Anker ₄ , Deepak L Bhatt ₅ , Javed Butler ₆ , David Z I Cherney ₇ , William G Herrington ₈ , Silvio E Inzucchi ₉ , Meg J Jardine ₁₀ , Chih-Chin Liu ₁₁ , Kenneth W Mahaffey ₁₂ , Darren K McGuire ₁₃ , John J V McMurray ₁₄ , Bruce Neal ₁₅ , Milton Packer ₁₆ , Vlado Perkovic ₃ , Marc S Sabatine ₁₇ , Scott D Solomon ₁₈ , Natalie Staplin ₈ , Michael Szarek ₁₉ , Muthiah Vaduganathan ₁₈ , Christoph Wanner ₂₀ , David C Wheeler ₂₁ , Stephen D Wiviott ₁₇ , Faiez Zannad ₂₂ , Hiddo J L Heerspink ₂₃

Affiliation

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Department of Renal Medicine, Royal North Shore Hospital, Sydney, NSW, Australia.
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Department of Cardiology and Berlin Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Baylor Scott and White Research Institute, Dallas, TX, USA; Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA.
Department of Medicine, Division of Nephrology, Toronto General Hospital, ON, Canada.
Renal Studies Group, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Section of Endocrinology, Yale School of Medicine, New Haven, CT, USA.
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, NSW, Australia.
Merck, Rahway, NJ, USA.
Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
University of Texas Southwestern Medical Center and Parkland Health, Dallas, TX, USA.
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
Baylor University Medical Center, Dallas TX, USA; Imperial College, London, UK.
TIMI Study Group, Boston, MA, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Division of Cardiology, University of Colorado School of Medicine, Aurora, CO, USA; Colorado Prevention Center Clinical Research, Aurora, CO, USA; State University of New York, Downstate Health Sciences University, Brooklyn, NY, USA.
Department of Clinical Research and Epidemiology, Comprehensive Heart Failure Centre, University Hospital, Würzburg, Germany.
Department of Renal Medicine, University College London, London, UK.
Université de Lorraine, Inserm, Center d'Investigations Cliniques, Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

SGLT2 inhibitors and GLP-1 receptor agonists both improve cardiovascular and kidney outcomes in patients with type 2 diabetes. We sought to evaluate whether the benefits of SGLT2 inhibitors are consistent in patients receiving and not receiving GLP-1 receptor agonists.

中文翻译：

SGLT2 抑制剂联合和联合胰高血糖素样肽 1 受体激动剂的疗效和安全性：随机对照试验的 SMART-C 合作荟萃分析

SGLT2 抑制剂和 GLP-1 受体激动剂均可改善 2 型糖尿病患者的心血管和肾脏预后。我们试图评估 SGLT2 抑制剂在接受和未接受 GLP-1 受体激动剂患者中的益处是否一致。

更新日期：2024-07-08

点击分享查看原文

点击收藏

阅读更多本刊新发论文